Key highlights
- 13 out of 16 participants achieved at least a 50% reduction in glucose infusion rate (GIR)
- 12 participants were able to completely discontinue intravenous glucose therapy during the study
- Trial achieved statistical significance by exceeding the required threshold of 9 responders out of 16
- No drug-related safety findings were attributed to ersodetug during the treatment period
- Company expects to report full topline results and statistical analysis by mid-December 2026
Clinical Trial Performance
Rezolute’s Phase 3 upLIFT study focused on patients with tumor hyperinsulinism, a rare metabolic condition characterized by excessive insulin production leading to severe hypoglycemia. The open-label trial enrolled 16 participants, including 12 with insulinomas and four with non-islet cell tumors. Preliminary data evaluated on November 5, 2026, confirmed that 81% of participants met the primary efficacy goal of reducing their glucose infusion rate by at least half. Notably, the majority of these responders successfully transitioned off intravenous glucose entirely, indicating a potential shift in the management of these ultra-rare conditions.
Down 7.5% since our story on 13 Nov: $3.87 when we broke it → $3.58 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $3.70 |
|---|---|
| 20 Oct | $3.70 |
| 21 Oct | $3.70 |
| 22 Oct | $3.86 |
| 23 Oct | $3.85 |
| 26 Oct | $3.82 |
| 27 Oct | $4.11 |
| 28 Oct | $4.22 |
| 29 Oct | $4.12 |
| 30 Oct | $3.95 |
| 2 Nov | $3.88 |
| 3 Nov | $4.01 |
| 4 Nov | $3.96 |
| 5 Nov | $3.64 |
| 6 Nov | $3.88 |
| 9 Nov | $3.87 |
| 10 Nov | $4.02 |
| 11 Nov | $4.07 |
| 12 Nov | $3.87 |
| 13 Nov | $3.65 |
| 16 Nov | $3.58 |
Regulatory Pathway and Significance
The achievement of the primary endpoint marks a critical milestone for Rezolute as it prepares for regulatory submissions. By demonstrating that ersodetug can significantly alleviate the need for continuous intravenous glucose, the company addresses a major unmet need in the treatment of refractory hypoglycemia. Rezolute plans to engage with the U.S. Food and Drug Administration in the first quarter of 2027. Success in this tumor HI cohort complements the company's broader development program, which also includes congenital hyperinsulinism, potentially positioning ersodetug as a versatile treatment for multiple forms of the disease.
Business and Pipeline Overview
Based in Redwood City, California, Rezolute is a late-stage biotechnology firm specializing in metabolic diseases. Its primary asset, ersodetug, is an investigational monoclonal antibody designed to block insulin receptors, thereby mitigating the effects of excess insulin. Beyond the upLIFT study for tumor HI, the company is actively developing therapies for congenital hyperinsulinism and diabetic macular edema. Rezolute’s strategy focuses on ultra-rare indications where existing treatment options are limited or nonexistent, often utilizing expanded access programs to gather early evidence of clinical utility for its lead candidates.
Management Perspective
“We are thrilled with this outcome and what it means for individuals living with tumor hyperinsulinism. Notably, these results substantially mirror the powerful outcomes that we have observed over the last few years in our expanded access program.”
Management commentary
“We believe that we are well positioned to advance both congenital HI and tumor HI into the approval process next year and we look forward to discussions with FDA in the first quarter of 2027.”
| Share price | $3.87 |
|---|---|
| Market cap | $374M |
| 1-month price change | -16.05% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Rezolute, Inc. announcing positive preliminary results from its Phase 3 upLIFT study of ersodetug.
Track Rezolute, Inc. live
Get the next Rezolute, Inc. SEC filing seconds after it lands.




